43 0 2

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Company Highlights

  • Robust pipeline in oncology, autoimmunity and infectious diseases
  • Partners include Boehringer Ingelheim, Gilead, Pfizer and Servier
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position and blue-chip investor base
  • Experienced management team and highly collaborative corporate culture 
Learn more

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

In the News

All News

February 19, 2013 | BioWorld
Bispecific Antibodies Capturing Great Deal of Industry Interest

January 07, 2013 | Washington Business Journal
MacroGenics Could Get $1B Payday

January 07, 2013 | Dow Jones Business News
MacroGenics Strikes Another Deal; Gilead Alliance Could Yield More Than $1 Billion

January 07, 2013 | BioCentury Extra
MacroGenics, Gilead in mAb DART Deal

January 07, 2013 | Fierce Biotech
Gilead and Biotech Strike Antibody Deal Worth North of $1.1B--Maybe

January 07, 2013 | BioWorld
MacroGenics DART Platform Grabs Potential $1B Gilead Deal

November 19, 2012 | The Pink Sheet
How to Place Bets on Early Oncology Assets

October 01, 2012 | Drug Discovery News
A Picture Perfect Focus

September 27, 2012 | Fierce Biotech
10 Next-gen Biologics Platforms to Watch

September 21, 2012 | "The Pink Sheet" Daily
MacroGenics Strikes Second Oncology Partnership with Servier

September 20, 2012 | Washington Business Journal
Servier Doubles Down on Rockville's MacroGenics

September 20, 2012 | BioCentury
MacroGenics, Servier in Second Cancer mAb Option Deal

September 20, 2012 | BioWorld Today
MacroGenics 'Serves' DART Deal Worth Potential $1B

September 20, 2012 | Wall Street Journal
The Daily Start-Up: MacroGenics Could Earn More Than $1B Through New Servier Alliance

September 20, 2012 | Fierce Biotech
MacroGenics Banks $20M in Potential $1.1B Cancer-Drugs Deal with Servier

May 01, 2012 | START-UP
The Hype and Hope of Cancer Stem Cell Therapeutics

December 23, 2011 | Gazette.Net
MacroGenics, BrainScope Among Bioscience Winners

December 01, 2011 | Bio World
MacroGenics 'Serves' Early Stage Antibody Deal: Potential $450M

December 01, 2011 | Fierce Biotech
MacroGenics Pockets $20M in $450 Deal with Servier

December 01, 2011 | Washington Business Journal
MacroGenics Inks Pharma Deal Worth up to $450 Million

November 30, 2011 | "The Pink Sheet" Daily
Servier, MacroGenics Forge Option Deal for Cancer Drug

July 14, 2011 | Medpage Today
ADA: Drug Misses Type 1 Goal, but May Help Beta Cells

June 07, 2011
Why Diabetes Prevention Might Work When Treatment Doesn't

June 07, 2011 | Wall Street Journal
Trying to Prevent Type 1 Diabetes

April 28, 2011 | Inside Blood
DARTs Take Aim at BiTEs

January 18, 2011 | Nature Biotechnology
Boehringer Splashes out on Bispecific Antibody Platforms

December 17, 2010 | Drug Discovery News
MacroGenics Hits Winning Target

October 27, 2010 | Gazette
MacroGenics Deal Worth up to $2.1 Billion

October 27, 2010 | Fierce Biotech
On a Roll, MacroGenics Inks Pfizer Deal

October 27, 2010 | Dow Jones Venture Wire
Shrugging Off Bad Break, MacroGenics Sign Boehringer, Pfizer Deals

October 26, 2010 | The Pink Sheet
Pfizer, Boehringer Ingelheim Tap MacroGenics in Separate Deals

October 26, 2010 | Genetic Engineering & Biotechnology News
BI Taps MacroGenics in Multibillion-Dollar Deal for Antibody Development

October 26, 2010 | BioWorld Today
Bullseye: MacroGenics Back on Target with Double DART Deals

October 26, 2010 | Fierce Biotech
MacroGenics Bounces Back with $2.16B Boehringer Pact

October 26, 2010 | BioCentury
MacroGenics in Pair of Antibody Deals

October 15, 2010 | Genetic Engineering and Biotechnology News
Stem Cell Therapies Make Steady Progress

September 01, 2010 | Chicago Tribune
Clinical Trials Aim to Find Help for West Nile Victims

April 01, 2010 | TrialNet E-News
Can Teplizumab Prevent or Delay Type 1 Diabetes?

August 13, 2009 | Science Business Exchange
Dousing Diabetes' Flames

August 06, 2009 | JDRF Countdown to a Cure
The Progression of Anti-CD3 Trials

July 27, 2009 | Washington Business Journal
D.C. Area Contains Job-Seeking Startups

July 24, 2009 | Gazette
Biotech Industry In Battle Over Data

July 03, 2009 | Washington Business Journal
Biotech: The Next Generation

June 30, 2009 | USA Today
Experiment Seeks To Head Off Type 1 Diabetes

June 26, 2009 | Washington Business Journal
Local Biotechs Search For Partners To Help Them Survive

March 23, 2009 | The Washington Post
No Money, No Buyers For Struggling Biotech Firms

September 26, 2008 | BioWorld Today
MacroGenics Raises $25M To Boost Stem Cell Line

September 26, 2008 | Washington Business Journal
New Venture Round Gives MacroGenics $25M Boost

September 25, 2008 | The Washington Post
Biotech Raises $25 Million In Financing

August 25, 2008 | BioWorld Today
86 Years After Insulin, Type I Diabetes Drugs Promise More

July 18, 2008 | The Washington Post
MacroGenics Buys Drug Developer To Bolster Cancer Work

July 17, 2008 | Washington Business Journal
MacroGenics Buys California-Based Raven Biotechnologies

July 17, 2008 | BioWorld Today
MacroGenics Boosts Anticancer Pipeline With Raven Acquisition

January 17, 2008 | Forbes
Delaying Diabetes

December 01, 2007 | Nature Biotechnology
Antivirals Become A Broader Enterprise

October 19, 2007 | Washington Post
Rockville Firm Deals Drug Rights to Lilly

October 19, 2007 | BioWorld Today
MacroGenics, Lilly Ink $1B Deal For Diabetes Drug Teplizumab

October 18, 2007 | Washington Business Journal
MacroGenics To Sell Rights To Lead Product To Eli Lilly

August 03, 2007 | Washington Business Journal
MacroGenics Begins Final Testing Of Diabetes Drug

January 04, 2007 | Washington Business Journal
MacroGenics Wins $2M Grant For Diabetes Drug

July 31, 2006 | The Washington Post
3 Big Deals Push Venture Funding To 4-Year Peak

May 17, 2006 | Washington Business Journal
MacroGenics Raises $45M In Third Round Of Funding

April 24, 2005 | nature.com
Development Of A Humanized Monoclonal Antibody With Therapeutic Potential Against West Nile Virus

February 09, 2005 | PNAS.org
Selective Blockade Of Inhibitory Fc Receptor Enables Human Dendritic Cell Maturation With IL-12p70 Production And Immunity To Antibody-Coated Tumor Cells

News Archive: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All